



Press release 5th September 2017

Fidelta announces an extension of its drug discovery service agreement with Heptares Therapeutics

Zagreb, Croatia, 5th September 2017 – Fidelta, a Galapagos company, is pleased to announce the continuation of an agreement with Heptares, whereby Fidelta will provide medicinal chemistry, DMPK and pharmacology services to advance Heptares' drug discovery programs against emerging GPCR targets.

Adrijana Vinter, Managing Director, Fidelta commented, "We are excited to continue working together with Heptares on integrated projects supporting discovery of new medicines using Fidelta's extensive scientific expertise."

Giles Brown, Director of Medicinal Chemistry at Heptares, said "Heptares is pleased to expand its drug discovery agreement with Fidelta. The company has demonstrated good value for Heptares with a focus on quality, fast turn-around and speed of delivery across a range of services."

About Fidelta

Fidelta, a wholly-owned subsidiary of Galapagos N.V., is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development. Fidelta has developed a new macrocyclic drug discovery platform, FideltaMacro.TM

Fidelta's objective is to deliver efficacious, safe and differentiated pre-clinical candidates for its clients. For more information, visit www.fidelta.eu

About Heptares Therapeutics

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, MorphoSys, PeptiDream, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.osei.com.

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan; StaR® is a registered trademark in the EU and Japan.

More information:

Fidelta d.o.o.
Adrijana Vinter, Managing Director
Tel: +385 1 8886395
fidelta@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Fidelta, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Fidelta expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.